Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Beyond Meat Inc (BYND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Beyond Meat Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Beyond Meat Inc trades at $0.68 (market cap $366.00M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 12.3× Beyond Meat Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BYND | |
|---|---|---|
Market Cap | $4.49B | $366.00M |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $4.28 |
52-Week Low | $20.06 | $0.52 |
Enterprise Value | $3.69B | $675.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BYND trades at $0.7102, down slightly by 0.01% on the day, with a neutral technical signal and bearish moving averages. The company reported a net income of $178.01M in 2025, a significant turnaround from prior losses, though revenue declined to $275.50M. Recent news highlights expansion of Beyond Steak Filet into major retailers like Meijer and Wegmans, alongside new product launches such as Beyond Immerse protein drinks, aiming to revive growth amid challenging sales trends.
The outlook remains cautious due to persistent revenue declines and negative cash flow from operations, offset by strong profitability margins and positive net income. Risks include execution challenges in new product categories and high sell-side analyst skepticism, with 57.14% recommending sell. Investment opportunity hinges on successful turnaround efforts driving sustainable top-line growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
